Dr Adam R Winstock MBBS, BSc, MSc, MRCP, MRCPsych, FAChAM, MD
Clinical Senior Lecturer, Honorary Consultant Psychiatrist
|contact this person|
|tel||020 7848 0207|
|address||National Addiction Centre|
Division of Psychological Medicine & Psychiatry, Kings' College London
PO Box 48 - Addiction Sciences Building
4 Windsor Walk
London SE5 8AF
|location|| level one|
3 - 4 Windsor Walk
I trained as physician before undertaking my psychiatry training at the Maudsley and Royal Bethlem Hospitals in 1995. I am a clinician, teacher and researcher. I spent 7 years in Australia as a senior clinician and educator before returning to the IOP in April 2009. I retain a conjoint academic position with the National Drug and Alcohol Research Centre at UNSW in Sydney. I am interested in optimising health outcomes for those in drug treatment by increasing thier knowledge and understanding about treatment. I want to support those who use drugs to access accurate, credible and practical information so they can reduce thier own risk of harm and look out for others that they care for.
|Lecturer||Clinical & Public Health Aspects of Addiction|
(Course under review) » Masters (MSc)
Last 3 years publications only ( excluding textbooks, monographs and guidelines)
Winstock AR, Mitcheson L, De Luca P, Davey Z, Schiffano F ‘mephedrone – new kid on the block’ in press Addiction
Winstock AR, Lintzeris N,Lea T Should I Stay or Should I go ‘coming off methadone and buprenorphine-what patients fear, want and have tried’. In pressInt J Drug Policy
Winstock AR, Ford C, Witton J Managing cannabis dependence and withdrawal in primary care. BMJ 2010;340:c1571
Winstock AR, Marsden J, Mitcheson L What should be done about mephedrone BMJ 2010;340:c1605
Winstock AR, Ramsey Legal Highs a Challenge for Policy makers 2010 Mar 19. [Epub ahead of print] Addiction
Winstock AR, Sheridan J, Lea T Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia Addiction; Volume 105 Issue 2, Pages 335 – 342
Winstock AR, Lea T Sheridan J.Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.Subst Use Misuse. 2010;45(1-2):240-52.
Winstock AR, Lintzeris N, Lea T. Why do patients report transferring between methadone and buprenorphine?.Drug Alcohol Rev. 2009 Nov;28(6):686-7.
Larance B, Degehardt L, Mattick R, Bell J, Lintzeris N, Winstock AR, Ali R "Injection of medications used in opioid substitution treatment in Australia following the introduction of a mixed partial agonist-antagonist formulation" Medical Journal of Australia August 2009
Winstock AR, Lea T, Jackson A methods and motivations for buprenorphine diversion J Addict Dis. 2009;28(1):57-63.
Winstock AR, Lea T, Copeland J. Lithium carbonate in the management of cannabis withdrawal J Psychopharmacol. 2009 Jan;23(1):84-93t)
Winstock AR, Nittis M, Whitton G, Lea T. Opioid dependent patients’ experiences and attitudes on having their injecting sites examined Int J Drug Policy 2009 Jan;20(1):85-9.
Winstock AR, Lea T Evaluation of a training program to improve clinicians’ assessment of patient stability. Drug Alcohol Rev. 2009 Jul;28(4):353-9.
Winstock AR, Lea T, Fettell Pilot evaluation of an educational DVD to engage in and out of treatment drug users. Drugs, Education, Policy and Prevention. April 2009; 16(2): 182–192
Winstock AR, Lea T, Bath N, Madden A. Knowledge about methadone and buprenorphine by those in treatment for opioid dependence in NSW Drugs, Education, Policy and prevention. Vol 16. Issue 2. 2009. 182-192
Lea T, Sheridan J, Winstock A. Consumer satisfaction with opioid treatment services at community pharmacies in Australia. Pharm World Sci. 2008 Dec;30(6):940-6
Winstock AR, Lea T, Sheridan J Prevalence of methadone and buprenorphine diversion and injection from community pharmacies in NSW. International J Drug Policy. 2008 Dec;19(6):450-8.
Madden A, Lea T, Bath N, Winstock AR Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. Drug Alcohol Rev. Drug Alcohol Rev. 2008 Mar 31:1-8.
Winstock AR, Lea T, Sheridan. Patients’ help-seeking behaviours for health problems associated with methadone and buprenorphine treatment. Drug Alcohol Rev. 2008 Jul;27(4):393-7.
Bunker J, Winstock AR, Zwar N, "GP involvement in caring for patients with opioid dependence" Australian Family Physician. Vol 37, No 1/2 p 57-60 2008
Winstock AR, Lea T, Safe storage of methadone takeaway doses: a survey of patient practice. Australian and New Zealand Journal of Public Health 31 (6), 526–528 2007
Bell J , Shanahan M, Mutch C, Rea F, Ryan A, Batey R, Dunlop A, Winstock A A randomized trial of effectiveness and cost effectiveness of supervised versus unsupervised administration of buprenorphine-naloxone for heroin dependence. Addiction 2007
Winstock AR, Lea T, Ritter A. The impact of community dispensing fees on the introduction of buprenorphine-naloxone in Australia. Drug and Alcohol Review, 2007, 26:4,411-416.
McCambridge J, Winstock AR, Mitcheson L, Hunt N. Five-year trends in patterns of hallucinogen use among people in dance contexts in the United Kingdom. Eur Addict Res. 2007;13(1):57-64
Mitcheson L1,2, McCambridge J2, Bryne A3, Hunt N1, Winstock AR5 Sexual health risk among dance drug users: cross-sectional comparisons with nationally representative data. International J Drug Policy (on line June 2007)
last updated: Friday, September 10, 2010